WHO advisory committee on variola virus. Report of 15th meeting
Very good reading. Sounds like we're getting closer to FDA approval. Also not much interest in funding other antivirals with ST 246 and CMX001 nearly approved. No further need for primate testing for us although FDA wants intradermal rabbit pox model.
Major advances have been made in this field. Two compounds, tecovirimat (ST-246; Arestvyr) and brincidofovir (CMX001), which are active and have different mechanisms of action, are well advanced along the regulatory pathway to licensure for smallpox. Tecovirimat has been tested in many animal models and has demonstrated unequivocal protection against orthopoxviruses, including variola virus, in these models. The US FDA has requested additional limited studies with the intradermal rabbitpox model and the intranasal ectromelia model in mice but stated that, at present, more work with live variola virus is not needed for these compounds. Despite not being licensed, ST-246 has been purchased for the US Strategic National Stockpile. A series of other potential compounds are in much earlier stages of development as medical countermeasures against smallpox.